Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $259,594 | $227,934 | $208,859 | $165,615 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Cost of Goods Sold | $164,865 | $146,551 | $136,145 | $95,429 |
| Gross Profit | $94,729 | $81,383 | $72,714 | $70,186 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| R&D Expenses | $0 | $13,242 | $15,265 | $11,488 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $71,486 | $50,493 | $51,934 | $40,162 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $0 | -$670 |
| Operating Expenses | $71,487 | $63,736 | $67,199 | $50,980 |
| Operating Income | $23,242 | $17,647 | $5,514 | $19,205 |
| % Margin | 9% | 7.7% | 2.6% | 11.6% |
| Other Income/Exp. Net | $3,088 | $6,812 | -$909 | $3,040 |
| Pre-Tax Income | $26,330 | $24,459 | $4,605 | $22,246 |
| Tax Expense | $7,343 | $8,286 | $2,404 | $6,331 |
| Net Income | $18,986 | $16,173 | $2,201 | $15,914 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS | 385.71 | 328.59 | 44.72 | 323.35 |
| % Growth | 17.4% | 634.8% | -86.2% | – |
| EPS Diluted | 385.71 | 328.59 | 44.72 | 316.19 |
| Weighted Avg Shares Out | 49 | 49 | 49 | 49 |
| Weighted Avg Shares Out Dil | 49 | 49 | 50 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $221 | $97 | $17 | $8 |
| Interest Expense | $1,627 | $947 | $635 | $230 |
| Depreciation & Amortization | $20,099 | $17,888 | $19,409 | $10,954 |
| EBITDA | $48,056 | $43,294 | $24,924 | $29,492 |
| % Margin | 18.5% | 19% | 11.9% | 17.8% |